Generation and Long-Term Maintenance of Human iPSC-Derived Cerebral Organoids Using a Modified SFEBq Embedded-Matrigel Protocol

Each batch starts from one iPSC line and produces 96 organoids (one V-bottom plate). Three independent batches per line are generated to assess reproducibility. Embedded vs. non-embedded arms are compared head-to-head. Time points for fixation/analysis: day 7 (EB), day 11 (neural induction), day 18 (neuroepithelial expansion, post-embedding), day 40 (early neurogenesis), day 60 (deep-layer neurons). 8-12 organoids per condition per time point are sampled for cryosectioning; organoid diameter is tracked longitudinally on 24 organoids/batch.

BSL-1/BSL-2 practices for human iPSC-derived material in a Class II cabinet. Matrigel is a murine-tumor-derived basement membrane — handle on ice, avoid aerosols, treat as biological waste. 2-mercaptoethanol is toxic and malodorous; dispense in a fume hood. PFA in a fume hood with aldehyde waste collection. Cryostat blades and OCT-frozen sectioning require sharps precautions and cryo-gloves. Decontaminate spent organoid medium with 10% bleach. Orbital shakers/bioreactors run inside the incubator — secure vessels to prevent spills.

Positive structural control: organoids fixed at day 18 should show N-cadherin+ apical surfaces lining lumens (polarity readout). Negative control: omission of dual-SMAD inhibitors yields disorganized, non-neural aggregates lacking PAX6 rosettes. Non-embedded arm controls for the contribution of Matrigel scaffolding. Secondary-only sections control for nonspecific antibody binding. A reference line with documented cortical differentiation anchors batch quality. Y-27632 vehicle (water) control on aggregation confirms survival effect.

By day 11, smooth translucent neuroepithelium at aggregate edges. By day 18, multiple polarized rosettes with apical N-cadherin and basal PAX6+/SOX2+ progenitors. By day 40, expanded ventricular-zone-like regions with Ki67+ proliferation at the apical surface and emerging TBR1+ neurons basally; organoid diameter 1-3 mm. By day 60, distinct deep-layer CTIP2+/TBR1+ neurons. Healthy organoids have a thin (<200 µm) necrotic core; loss of polarity or diffuse PAX6 indicates failure.

• Human iPSC line (karyotype-normal, p25-p45)
• 96-well ultra-low-attachment V-bottom plates
• mTeSR Plus + 50 µM Y-27632 (aggregation day)
• Neural induction medium: DMEM/F12 + 20% KnockOut Serum Replacement + 1x GlutaMAX + 1x NEAA + 0.1 mM 2-mercaptoethanol
• Dual-SMAD inhibitors: SB431542 (10 µM) + LDN-193189 (100 nM) or Dorsomorphin (1 µM)
• Neural differentiation medium: 1:1 DMEM/F12:Neurobasal + 0.5x N2 + 1x B-27 minus vitamin A + 1x GlutaMAX + insulin (2.5 µg/mL)
• Growth-factor-reduced Matrigel (on ice)
• Maturation medium: as above with B-27 + vitamin A, + BDNF/GDNF optional
• Antibodies: anti-PAX6, anti-SOX2, anti-TBR1, anti-CTIP2/BCL11B, anti-N-cadherin (apical), anti-Ki67
• 4% PFA; 30% sucrose; OCT compound; DAPI

To generate human iPSC-derived cerebral organoids via serum-free embryoid-body (SFEBq) aggregation followed by neural induction, Matrigel embedding to support neuroepithelial expansion, and spinning/orbital culture for maturation, yielding organoids that develop polarized neural rosettes, PAX6+/SOX2+ ventricular-zone-like progenitor regions, and TBR1+/CTIP2+ deep-layer neurons by day 40-60.

1. Day 0: Dissociate iPSCs to single cells (Accutase), seed 9,000 cells/well in 150 µL mTeSR Plus + 50 µM Y-27632 into V-bottom plates; centrifuge 100 x g 3 min to aggregate.
2. Days 1-6: Daily half-medium changes; transition to neural induction medium with SB431542 + LDN-193189 from day 3.
3. Day 7: Transfer aggregates to neural differentiation medium; assess for translucent neuroepithelial edges.
4. Day 8-9: Embed each aggregate in a ~15 µL Matrigel droplet on a dimpled Parafilm sheet; gel 30 min at 37 C; release into a 10 cm dish.
5. Days 9-15: Static culture in neural differentiation medium, changing every other day; expect neuroepithelial budding.
6. Day 16 onward: Transfer to an orbital shaker (80 rpm) or spinning bioreactor in maturation medium; change medium 2-3x/week.
7. Sampling: fix organoids in 4% PFA (2-4 h, 4 C), cryoprotect in 30% sucrose, embed in OCT, cryosection at 16 µm, and immunostain.

Independent variables: Matrigel embedding (yes/no), culture format (static vs. orbital/spinner), differentiation day. Dependent variables: organoid diameter, number/size of PAX6+/SOX2+ ventricular-zone-like regions, neural rosette polarity (N-cadherin apical localization), TBR1+/CTIP2+ neuron fraction, necrotic-core area. Controlled variables: starting cell number (9,000/well), medium formulation and change schedule, shaker speed (80 rpm), incubation 37 C/5% CO2, organoid age at sampling.

Forced aggregation of a defined cell number (9,000 cells/well) in low-attachment V-bottom plates, combined with dual-SMAD inhibition during neural induction, will bias differentiation toward dorsal telencephalic fate. Embedding day-7 aggregates in Matrigel will provide a basement-membrane scaffold that promotes apicobasally polarized neuroepithelium and budding, producing organoids with reproducible cortical architecture and reduced batch variability versus non-embedded controls.

Cryosection images acquired on confocal at 10-20x are quantified in Fiji: ventricular-zone regions identified by PAX6+/SOX2+ clustering around N-cadherin+ lumens; counted and measured (area, radial thickness). TBR1+/CTIP2+ neurons counted as fraction of DAPI+ in the basal layer. Organoid diameter measured from brightfield using a calibrated scale bar. Necrotic-core area thresholded from DAPI fragmentation. Data tabulated per organoid and averaged per batch.

1. Aggregates fail to form/are loose: increase Y-27632 to 50 µM and confirm single-cell dissociation; re-centrifuge during aggregation. 2. No neuroepithelium by day 11: dual-SMAD inhibitor lots inactive or added too late — start SB/LDN by day 3 and verify stocks. 3. Large necrotic cores: insufficient nutrient/oxygen exchange — move to orbital shaking earlier (day 14-16) and reduce organoid crowding. 4. Disorganized, non-polarized tissue: Matrigel too dilute or organoids damaged during embedding — use cold growth-factor-reduced Matrigel and handle gently. 5. High batch variability: standardize iPSC pluripotency QC before starting and fix aggregation cell number precisely.

Embedded vs. non-embedded organoid diameter and VZ-region counts compared by two-tailed Welch's t-test (alpha = 0.05). Batch reproducibility assessed by nested ANOVA (organoid within batch within line) in R (lme4). n = 3 batches, 8-12 organoids/batch/time point. Multiple time points corrected with Bonferroni. Coefficient of variation in diameter across batches reported; CV < 25% considered acceptable for organoid systems. Data shown as mean +/- SEM.